Mantle cell lymphoma diagnostic study of choice
|
Mantle cell lymphoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Mantle cell lymphoma diagnostic study of choice On the Web |
|
American Roentgen Ray Society Images of Mantle cell lymphoma diagnostic study of choice |
|
Risk calculators and risk factors for Mantle cell lymphoma diagnostic study of choice |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ali Akram, M.B.B.S.[2]
Overview
Tissue biopsy (nodal or extranodal) is the gold standard test for the diagnosis of mantle cell lymphoma.
Diagnostic Study of Choice
Study of choice
- Tissue biopsy (nodal or extranodal) is the gold standard test for the diagnosis of mantle cell lymphoma.
Histology
- The microscopic histological findings can be found here.
Immunohistochemistry
- CD19, CD20, CD22, CD43, CD79a, CD5, and FMC7 typically are positive, whereas CD23, CD10, CD200, and BCL6 are usually negative.[1][2]
- Cyclin D1 is positive in majority of the cases.
- SOX11 expression is useful if cyclin D1 is negative.
- Ki-67 should also be included in the initial work-up. Ki-67 proliferation index of less than 30% is associated with a favorable prognosis.[3][4]
Fluorescence in situ hybridization (FISH)
- FISH can be used to detect the translocation t(11;14), which is found in most of MCL patients.[5]
Karyotyping:
- Karyotyping can also be used to detect the translocation t(11;14), which is found in most of MCL patients.[6]
References
- ↑ Francesco Bertoni, Emanuele Zucca & Finbarr E. Cotter (2004). "Molecular basis of mantle cell lymphoma". British journal of haematology. 124 (2): 130–140. PMID 14687022. Unknown parameter
|month=ignored (help) - ↑ Chan Yoon Cheah, John F. Seymour & Michael L. Wang (2016). "Mantle Cell Lymphoma". Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34 (11): 1256–1269. doi:10.1200/JCO.2015.63.5904. PMID 26755518. Unknown parameter
|month=ignored (help) - ↑ Olaf Determann, Eva Hoster, German Ott, Heinz Wolfram Bernd, Christoph Loddenkemper, Martin Leo Hansmann, Thomas E. F. Barth, Michael Unterhalt, Wolfgang Hiddemann, Martin Dreyling & Wolfram Klapper (2008). "Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group". Blood. 111 (4): 2385–2387. doi:10.1182/blood-2007-10-117010. PMID 18077791. Unknown parameter
|month=ignored (help) - ↑ R. Schaffel, C. V. Hedvat, J. Teruya-Feldstein, D. Persky, J. Maragulia, D. Lin, C. S. Portlock, C. H. Moskowitz & A. D. Zelenetz (2010). "Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma". Annals of oncology : official journal of the European Society for Medical Oncology. 21 (1): 133–139. doi:10.1093/annonc/mdp495. PMID 20019090. Unknown parameter
|month=ignored (help) - ↑ Tsieh Sun, Mary Lowery Nordberg, James D. Cotelingam, Diana M. Veillon & John Ryder (2003). "Fluorescence in situ hybridization: method of choice for a definitive diagnosis of mantle cell lymphoma". American journal of hematology. 74 (1): 78–84. doi:10.1002/ajh.10356. PMID 12949897. Unknown parameter
|month=ignored (help) - ↑ Jordi Camps, Itziar Salaverria, Maria J. Garcia, Esther Prat, Silvia Bea, Jessica C. Pole, Lluis Hernandez, Javier Del Rey, Juan Cruz Cigudosa, Marta Bernues, Carlos Caldas, Dolors Colomer, Rosa Miro & Elias Campo (2006). "Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines". Leukemia research. 30 (8): 923–934. doi:10.1016/j.leukres.2005.11.013. PMID 16448697. Unknown parameter
|month=ignored (help)